Body Fat Effects of Atazanavir (ATV) and Efavirenz (EFV) Each Combined With Fixed-Dose Zidovudine (ZDV) and Lamivudine (3TC)

48-Week Results From the Metabolic Substudy of BMS-034

JG Jemsek, E Arathoon, M Arlotti, C Perez, N Sosa, V Pokrovskiy, M Giordano, A Thiry, M Soccodato

## **HIV and Body Fat Changes: Background**

## Effects of Current PI Treatment

- Treatment with existing PIs is associated with changes in body composition
  - IDV associated with accumulation of intra-abdominal (visceral) fat <sup>1</sup>
  - NFV associated with significant reduction in limb fat <sup>2</sup>
- Significant increases in cholesterol and triglycerides observed across existing PI class

## • FRAM Study <sup>3</sup>

 HIV+ patients have less limb and visceral fat compared to HIV- controls

<sup>1</sup> Miller KD *et al. Lancet* 1998; 351:871-875
 <sup>2</sup> Dubé *et al.* Abstract 27. 4<sup>th</sup> Lipodystrophy Workshop, San Diego, Sept 2002
 <sup>3</sup> Grunfeld C *et al.* XIV IAC, Barcelona, July 2002. TuOr158

# **Atazanavir Background**


- Once-daily azapeptide PI
  - $-C_{min}$  > protein-binding adjusted EC<sub>90</sub> for > 36 hr
- Low pill burden (2 capsules/day, 400 mg)
- Efficacy in naïve and experienced patients
- Favorable lipid profile (TC, fasting LDL-C, fasting TG)
- Does not inhibit insulin-mediated glucose transport via GLUT-4

## BMS-034 Metabolic Substudy Objectives

- To assess the effect of ATV on body composition by measuring the change from baseline through week 48 in:
  - Visceral adipose tissue (VAT)
  - Subcutaneous adipose tissue (SAT)
  - Total adipose tissue (TAT)
  - Appendicular, truncal, total body fat
- To assess changes in serum lipid levels, fasting glucose and insulin levels

# **Study Design**

Randomized, double-blind, double-dummy, active-controlled Treatment-naïve patients: HIV RNA ≥2000 c/mL, CD4 ≥100 cells/mm<sup>3</sup>



# **Exclusion Criteria**

- Uncontrolled hypercholesterolemia
- History of cardiac disease
- Triglyceride level >750 mg/dL
- Untreated hypogonadism
- Receipt of agents with metabolic changes

## Assessments

L4/L5 Cross Section Computerized Tomography (CT)

- Visceral Adipose Tissue (VAT)
- Subcutaneous Adipose Tissue (SAT)
- Total Adipose Tissue (TAT)

Dual Energy X-Ray Absorptiometry (DEXA)

- Appendicular fat
- Truncal fat
- Total body fat

# Analyses

- Analyses included all patients with assessments prior to dosing initiation and after Week 24
- Patients discontinued after Week 24: LOCF to Week 48 (n=2 [approx 4%] per group)
- Centralized readings performed at Tufts University

## BMS-034 Metabolic Substudy Patient Baseline Characteristics

	<b>ATV</b> N=111	<b>EFV</b> N=100	Total 034 N=805
Age, median, yr	30	29	33
Female, %	26	29	35
Race, % <i>Hispanic/Latino</i> White Other	49 45 6	48 45 7	37 33 30
IDU, %	8	14	6
AIDS, %	3	4	5
HIV RNA, median, log <sub>10</sub> c/mL	4.84	4.69	4.88
CD4 count, median, cells/mm <sup>3</sup>	328	323	282
BMI, median, kg/m²	23.5	23.2	23.5


# **Baseline Body Fat**

	ATV	EFV
Adipose tissue, median (cm <sup>2</sup> )	N=75	N=69
VAT	45.3	46.9*
SAT	136.9	125.9
TAT	188.9	183.8
Body fat, median (kg)	N=90	N=80
Appendicular	5.1	5.4
Truncal	6.9	6.5
Total body	13.0	13.0†

\*N=68, †N=79

2nd IAS Conference on HIV Pathogenesis and Treatment Paris, France. 13-16 July 2003 Oral Presentation LB-13

## **DEXA Results: Baseline and Week 48 (Mean)**



No significant difference for change from Baseline <u>within</u> treatment arms and <u>between</u> treatment arms for all compartments


## **DEXA Mean Ratios: Baseline and Week 48**

	ATV		EFV	
	Baseline	Week 48	Baseline	Week 48
Appendicular:TBF	0.42	0.42	0.43	0.42
Truncal:TBF	0.52	0.52	0.51	0.53

**TBF** = total body fat

2nd IAS Conference on HIV Pathogenesis and Treatment Paris, France. 13-16 July 2003 Oral Presentation LB-13

## CT Results: Baseline and Week 48 (Mean)



\*\* p<0.001, change from baseline within treatment</li>
\* p<0.05, change from baseline within treatment</li>

2nd IAS Conference on HIV Pathogenesis and Treatment Paris, France. 13-16 July 2003 Oral Presentation LB-13


## **CT Mean Ratios: Baseline and Week 48**

	A	ATV		EFV	
	Baseline	Week 48	Baseline	Week 48	
VAT:TAT	0.28	0.31	0.28	0.30	
VAT:SAT	0.44	0.50	0.42	0.46	
SAT:TAT	0.72	0.69	0.72	0.70	


Mean weight gain from baseline at Week 48: ATV, 2 kg; EFV, 0 kg

2nd IAS Conference on HIV Pathogenesis and Treatment Paris, France. 13-16 July 2003 Oral Presentation LB-13

## Lipids: Baseline and Week 48 (Median)



## Fasting Glucose and Insulin: Baseline and Week 48



# Conclusions

- ATV and EFV are associated with comparable and proportional effects in body fat distribution through Week 48
  - Modest fat increases were consistently noted in both groups (in all compartments)
  - There was no evidence of central adiposity by VAT to TAT ratios
  - There was no evidence of lipoatrophy
- The pattern of fat increase was consistent with successful disease treatment
- ATV treatment did not result in increases in TC, fasting LDL, or fasting TG
- Neither ATV nor EFV resulted in increases in insulin resistance indices

# Acknowledgments

TO ALL THE PATIENTS AND STUDY CENTER PARTICIPANTS

JG Jemsek,<sup>1</sup> E Arathoon,<sup>2</sup> M Arlotti,<sup>3</sup> C Perez,<sup>4</sup> N Sosa,<sup>5</sup> V Pokrovskiy,<sup>6</sup> M Giordano,<sup>7</sup> A Thiry,<sup>7</sup> M Soccodato<sup>7</sup>

<sup>1</sup>Jemsek Clinic PLLC, Huntersville NC, USA, <sup>2</sup>Hospital General San Juan de Dios, Guatemala, Guatemala, <sup>3</sup>Ospedale degli Infermi, Rimini, Italy, <sup>4</sup>Hospital Clínico de La Pontificia Universidad Católica, Santiago, Chile, <sup>5</sup>Consultorio Royal Center, Panama City, Panama, <sup>6</sup>Federal AIDS Center, Moscow, Russia, <sup>7</sup>Bristol Myers Squibb Company, Wallingford, CT, USA